Ifp Advisors, Inc Affimed N.V. Transaction History

Ifp Advisors, Inc

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Sep 06, 2022	BUY	$2.27 - $4.86 $2,610 - $5,589	1,150 New	1,150 $2,000
Q2 2022 Aug 12, 2022	SELL	$2.27 - $4.86 $2,610 - $5,589	-1,150 Closed	0 $0
Q2 2021 Jul 13, 2021	BUY	$7.78 - $11.4 $8,947 - $13,110	1,150 New	1,150 $10,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Ifp Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ifp Advisors, Inc with notifications on news.